Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights Visa, ExxonMobil Holdings and Pfizer

Read MoreHide Full Article

For Immediate Release

Chicago, IL – November 16, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa Inc. (V - Free Report) , ExxonMobil Holdings Corp. (XOM - Free Report) and Pfizer Inc. (PFE - Free Report) .

Here are highlights from Monday’s Analyst Blog:

Top Stock Reports for Visa, ExxonMobil & Pfizer

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., ExxonMobil Holdings Corp.and Pfizer Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Today's Featured Research Reports

Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the past year (+28.4% vs. +10.5%). Per the Zacks analyst, the company benefits from its strong global brand, extensive payments network and growth in digital transactions, cross-border payments and commercial solutions. Investments in agentic commerce, stablecoin settlement and strategic acquisitions should further strengthen its competitive position.

However, rising client incentives and marketing expenses are pressuring profitability. Uneven cash activity across regions, elevated valuation and persistent regulatory and litigation risks remain concerns.

(You can read the full research report on Visa here >>>)

ExxonMobil’s shares have outperformed the Oil and Gas - Integrated - International industry over the past six months (+12.6% vs. +8.3%). The Zacks analyst believes that the company benefits from low-cost production, an integrated business model and expansion opportunities in the Permian, Guyana and global gas markets. Technological innovation, cost discipline and higher-value products strengthen efficiency and long-term competitiveness.

Yet, exposure to commodity price volatility and changing energy demand remains a concern. Large-scale project execution and the energy transition also pose operational and strategic challenges.

(You can read the full research report on ExxonMobil here >>>)

Pfizer’s shares have underperformed the Large Cap Pharmaceuticals  industry over the past year (+22.8% vs. +33.7%). The Zacks analyst believes that the company faces significant patent expiration risks, while its near-term growth outlook remains subdued. Revenue pressure from losing exclusivity on key products could weigh on performance.

However, improving non-COVID product sales, new launches and acquisitions are supporting recovery. Pipeline investments in oncology and obesity offer longer-term growth opportunities, while its recent earnings surprise track record provides some encouragement.

(You can read the full research report on Pfizer here >>>)


 

Published in